Activating gain of function mutations are specifically related to medullary thyroid carcinoma (MTC) [4], while RET gene rearrangements have been reported in papillary thyroid carcinoma (PTC) [4], in lung cancer [5], and chronic myelomonocytic leukemia [6]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.